A patient-derived cell atlas informs precision targeting of glioblastoma

Patrik Johansson[1]†, **Cecilia Krona**[1]†, **Soumi Kundu**[1]†, **Milena Doroszko**[1], **Sathishkumar Baskaran**[1], **Linnéa Schmidt**[1], **Claire Vinel**[2], **Elin Almstedt**[1], **Ramy Elgendy**[1], **Ludmila Elfineh**[1], **Caroline Gallant**[1], **Sara Lundsten**[1], **Fernando J. Ferrer Gago**[4], **Aleksi Hakkarainen**[5], **Petra Sipilä**[5], **Maria Häggblad**[6], **Ulf Martens**[6], **Bo Lundgren**[6], **Melanie M. Frigault**[7], **David P. Lane**[8], **Fredrik Swartling**[1], **Lene Uhrbom**[1], **Marika Nestor**[1], **Silvia Marino**[2], **Sven Nelander**[1]***

[1] Department of Immunology Genetics and Pathology, Science for Life Laboratory, Uppsala University, SE

[2] Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK

[4] p53 Laboratory, Agency for Science, Technology and Research, Singapore 138648, SG

[5] Institute of Medicine, University of Turku, Turku, FI

[6] Department of Biochemistry and Biophysics, SciLifeLab, Stockholm University, Stockholm, SE

[7] Oncology Translational Medicine, AstraZeneca Pharmaceuticals, Boston, MA, US

[8] Dept of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, SE

† Shared first authorship

* Lead Contact, Corresponding Author, Email: sven.nelander@igp.uu.se

Summary

Glioblastoma (GBM) is a malignant brain tumor with few therapeutic options. The disease presents with a complex spectrum of genomic aberrations, but the pharmacological consequences of these aberrations are partly unknown. Here, we report an integrated pharmacogenomic analysis of 100 patient-derived GBM cell cultures from the Human Glioma Cell Culture (HGCC) cohort. Exploring 1544 drugs, we find that GBM has two main pharmacological subgroups, marked by differential response to proteasome inhibitors and mutually exclusive aberrations in *TP53* and *CDKN2A/B*. We confirm this trend in cell and in xenotransplantation models, and identify both Bcl-2 family inhibitors and p53 activators as potentiators of proteasome inhibitors for GBM treatment. We can further predict the responses of individual cell lines to several drug classes, presenting opportunities for drug repurposing and design of stratified trials. Our functionally profiled biobank provides a valuable resource for the discovery of new treatments for GBM.

Introduction

The pharmacological treatment of glioblastoma (GBM) remains one of the hardest challenges in cancer precision therapy. An increasing volume of genetic data has clarified that GBM tumors present with multiple and diverse genetic aberrations in receptor tyrosine kinase (RTK), p53 and other pathways (Brennan et al., 2013; Taylor et al., 2019). Despite these advances, current therapy is based on a combination of surgery, radiation, and temozolomide, resulting in a median survival of 14.6 months, of which a mere 2.5 months are attributed to the chemotherapy (Stupp et al., 2005). Targeted intervention against key recurrent oncogenes in the RTK pathways, EGFR and PDGFRA, does not improve overall survival in unselected cohorts (Lee et al., 2015; Reardon et al., 2015; Brown et al., 2008). The impact of tumor diversity on GBM pharmacology thus remains to be elucidated.

To address this challenge, collections of patient-derived GBM cell cultures provide us with a powerful tool to explore and define possible pharmacological responses in GBM (Pollard et al., 2009; Xie et al., 2015). The analysis of drug response across a panel of GBM cell cultures gives a relatively unbiased estimate of how drug responses vary, and their correlation (if any) with patient-specific factors, such as age, sex (**?**), frequent mutations, or transcriptional subtype (Verhaak et al., 2010; Wang et al., 2017). In recent work, Lee *et al.* demonstrated that patient-derived GBM cells treated with drugs approved for oncology indications - predominantly kinase inhibitors - respond in a manner that can be predicted based on their somatic mutations (Lee et al., 2018). Traditional GBM cell lines, such as U87MG (Allen et al., 2016), have also been included in comparative pharmaco-genomic screens of tumor cell lines from diverse tissue origins (Kutalik et al., 2008; Barretina et al., 2012; Garnett et al., 2012; **?**; Basu et al., 2013; Seashore-Ludlow et al., 2015; Iorio et al., 2016). Despite these advances, the number of drug classes analyzed in well-characterized patient-derived GBM cell cultures remains limited, and there is scarce data to connect common drug classes to cellular pathways in GBM.

Here, we report a systematic effort to define the known and unknown pharmacological subclasses of GBM. Our strategy connects pharmacological and genomic profiling of 100 patient-derived GBM cell cultures, with computational modeling, to identify (i) drugs and mechanisms-of-action with activity against primary GBM cells (ii) the key pathways associated to drug response; and (iii) combinatorial interventions based on drug-pathway associations **(Figure 1A)**. Previously, our laboratory has genetically characterized the Human Glioma Cell Culture (HGCC) resource of 48 public primary GBM lines, which has a broad distribution (Xie et al., 2015). The extended effort presented here aims to meet an unmet need for a large set of highly characterized cell models, with clinical annotations, comprehensive molecular information, as well as pharmacological and functional data.

From an unbiased survey of 1,544 compounds that comprise 116 mechanisms-of-action (MOA), we identify a set of 248 drugs with GBM activity after 72 hours of exposure. We use the variation in dose-dependent response to these drugs to define the main pharmacological classes of GBM and construct models that connect

each individual drug (and drug class) to pathways and individual markers. The resulting map substantially extends the set of drug categories that can be predicted with accuracy in GBM, defines 51 associations between drug classes and hallmark pathways, and nominate biomarkers for drugs with both oncology and non-oncology indications. We find that GBM cultures exist in two main functional classes, not captured by current subtype systems. The classes are characterized by mutually exclusive p53 mutation and deletion of the *CDKN2A/B* locus, and differential sensitivity to proteasome inhibitors, a class of drugs that block the cellular catalysis of ubiquitinated proteins, leading to a surge of reactive oxygen species (ROS) and apoptotic cell death (Richardson et al., 2005; Ling et al., 2003; Lipchick et al., 2016). Exploiting additional compounds targeting pathways linked to p53 and proteins encoded by the *CDKN2A/B* locus, we find that the resistance to proteasome inhibitors can be overcome by combinatorial targeting.

Our results underline the importance of the p53 and CDK pathways in GBM precision therapy and demonstrate that an integrated study of primary GBM cells profiled at multiple levels can reveal unexpected associations between pathways and drug response. The functionally characterized HGCC cell collection provides a resource, which we expect will enhance and expedite the development of new interventions against GBM.

Results

Patient-derived cell cultures recapitulate the known molecular heterogeneity of GBM

As our model for GBM drug response, we used 100 cultures from our Human Glioma Cell Culture (HGCC) collection at Uppsala University Hospital in Northern Europe, which underwent systematic genomic and pharmacological profiling **(Figure 1A, Table S1)**. For these cultures to be a model of GBM diversity, they should recapitulate several layers of glioblastoma heterogeneity, including molecular subtype, core pathway mutations, and chromosomal aberrations. We, therefore, established genomic background data for our cell cultures on several genomic platforms, which were compared to the corresponding molecular data from surgical GBM samples in The Cancer Genome Atlas (TCGA) (Brennan et al., 2013). Our primary cultures corresponded well to TCGA in terms of patient age, survival times, patient sex and molecular subtype (classical/proneural/mesenchymal system (Verhaak et al., 2010)) **(Figure 1B)**. Our cultures also shared the spectrum of driver genes observed in TCGA at similar frequencies **(Figure 1C, R=0.82)** and each culture retained genetic similarity to its source tumor (median of 27 mutations in common; 90% CI=18.5-31.75) **(Figure S1A-B)**. We noted a slight reduction in the gene copy number of *EGFR* locus amplification, **(Figure S1C-D)**, which we interpret as loss of extrachromosomal *EGFR* amplified genetic material unevenly distributed in mitosis as double minutes (Nikolaev et al., 2014). Still, the overall correlation of DNA copy number aberrations between our cell cultures and TCGA, however, was very high (R^2=0.93) **(Figure S1E-F)**. From this analysis, we conclude that our extended HGCC panel of primary cultures is genetically representative of GBM diversity as observed across patient tumors.

4

Accordingly, pharmacological profiling of a large sample of diverse primary cells should reveal informative associations to drug response.

Sensitivity to proteasome inhibitors defines two subclasses of GBM cells

To explore the drug sensitivity of primary GBM cultures, we first implemented a discovery screen to select drugs for subsequent analysis across all 100 cultures. The discovery screen **(Figure 2A, Phase 1)** was carried out using a library of 1544 annotated drugs, relevant for both oncology and other disease areas. Applying the library to 9 GBM cultures of different subtypes, we identified the drugs that reduced viability in at least 3/9 cultures. These hits were compiled into a 248 drug library for profiling the GBM cultures in our collection. We carried out drug profiling in two phases, with 52 cell cultures each **(Figure 2A, Phase 2-3)**. Drugs retained for phase 3 were the ones with the highest variability in viability response between cases. As determined by drug target databases (Drug Repurposing Hub and STITCH5), the library used had broad representation, covering 430 known drug targets, 118 mechanisms-of-action, and 21 disease areas **(Figure 2A-B, Table S2)**. Among the 30 most active compounds, 9 were previously unreported as candidates for GBM therapy **(Table S2)**.

In each GBM culture, the effect of a drug was summarised as an Area Under the dose-response Curve (AUC) score. Arranging these scores as a matrix of patient-derived cells (rows) and drugs (columns), we used hierarchical clustering to detect groups of cell cultures and drugs with strongly correlated behavior **(Figure 2C)**. Notably, the best-fitted clustering robustly separated the cell cultures into two clusters, defined by sensitivity or resistance to a single class of drugs; proteasome inhibitors targeting PSMB5 and other proteasome units **(Figure 2C)**. Graphing the dose-response curves for the six proteasome inhibitors in the data highlights the bimodal response to this category of drugs **(Figure 2D)**. In our clustering of compounds, several drug targets other than the top hit PSMB5 (p=$2.99 * 10^{-9}$) were non-randomly distributed across clusters, such as the dopamine receptor (DRD2, $p = 5.71 * 10^{-3}$), the muscarinic receptor (CHRM1, $p = 5.97 * 10^{-4}$), spindle poisons (TUBB, $p < 1 * 10^{-10}$), and BMP2 ($p = 5.24 * 10^{-6}$, all p-values corrected by Benjamini-Hochberg's (BH) method). Drugs targeting kinases EGFR and PDGFRA, which were strongly enriched as active against GBM cultures in the first screen (p<$1 * 10^{-5}$, BH-corrected, **Figure 2A**), did not exhibit such a significance, indicating that these are not the most promising candidates for therapy directed against specific GBM subgroups. Of note, we did not find a significant overlap between clusters of cell cultures and existing transcriptional subtypes. Also, unlike a recent report on sex differences in drug response (**?**), our data did not support that the drug sensitivities measured in our cohort were dependent on patient sex.

This analysis established that patient-derived GBM cells are primarily grouped by their sensitivity to proteasome inhibitors, and secondarily grouped by response to other classes of drugs. Since we found no evidence of an association between this grouping and obvious covariates such as GBM subtype or patient sex, we went on to investigate the data using an unbiased machine learning approach to identify associations between molecular

data and drug response.

Network analysis links proteasome inhibitors to the p53 pathway

Integrating the collected data, we constructed statistical network models of drug responses in the GBM cells, with two specific goals in mind. First, we aimed to understand how activation of cellular pathways related to drug response. Second, we aimed to define how well different classes of compounds can be predicted. To address the first problem, we computed the association between responses to individual drugs and 50 Hallmark pathways, using Gene Set Enrichment Analysis (GSEA), retaining drug-pathway associations with q-value < 0.1. We subsequently used information in the Drug Repurposing Hub database (Corsello et al., 2017) to group our compounds based on mechanism-of-action (MOA) and used a Fisher test to find strong associations between pathways and MOAs. We summarised the result as a network in which links are pathway-to-MOA links with p-value < 0.05 **(Figure 3A)**. The network linked proteasome inhibitors to the expression of p53 Hallmark genes, which was the most enriched Hallmark pathway in this regard (p=0.0043, Fisher's exact test with FDR correction). In total, 51 links were detected, containing both known relationships (e.g. between kinase inhibitors and cell cycle checkpoints) and interesting predictions (e.g. between sigma receptor inhibitors and lipid metabolism)**(Figure 3A)**.

Accurate prediction of drug responses in primary GBM cells

In extended network analyses, we asked if additional layers of genomic data (e.g. mutations or DNA methylations) were associated with drug response and if the effect of different drugs could be predicted with accuracy, based on specific biomarkers. For this, we used a machine learning method, in which drug response (AUC) was the predicted variable, and other data were used as covariates. For an unbiased search, we let two well-defined algorithms (random forest and elastic net) select variables from RNA, CNA, and other data types to predict each individual drug. We used the leave-one-out cross-validation correlation (CV-R) as a metric of predictive power, which estimates the ability of the collected data to predict prospectively the variation in response in unseen cases on a scale from 0 (no predictive power) to 1.0 (perfect predictions). Other versions of cross-validation, like leave-10-out, gave highly correlated results (Methods). Previous versions of this approach have been successfully evaluated for cell cultures of mixed lineage origins (Kutalik et al., 2008; Barretina et al., 2012; Garnett et al., 2012; **?**; Basu et al., 2013; Seashore-Ludlow et al., 2015; Iorio et al., 2016). However, there is so far limited experience of the performance of machine learning in a well-characterized cohort of primary GBM lines.

In primary GBM cultures, a majority of drugs (262) could be predicted at a CV-R greater than 0.33, with remarkably high CV-R for particular drugs, such as clomipramine (CV-R=0.76). Prediction power depended

on the drug category. For instance, proteasome inhibitors had a higher average predictive power (CV-R=0.44) than inhibitors of the tyrosine kinases EGFR, VEGFR and PDGFR (CV-R 0.37 to 0.41) **(Table S3)**. The machine learning algorithm identified an association between several members of the p53 Hallmark pathway (*CDKN1A*, *SESN1*) and the six different proteasome inhibitors (bortezomib, oprozomib, carfilzomib, MG-132, delanzomib, ixazomib) **(Figure 3B)**. Consistent with the GSEA result, the number of network connections between proteasome inhibitors and p53 pathway genes was higher than expected by random, taking into account the size of the p53 pathway (Fisher's exact test, FDR-corrected p value=0.0206). This suggests that a handful of markers in the p53 pathway can guide precision targeting using proteasome inhibitors. To further corroborate our cross-validation approach, we predicted the drug response in 10 cell cultures that were unseen by the algorithm, collected in a different hospital and profiled in a different center, and confirmed a differential response to bortezomib, measured by AUC **(Figure 3C)**.

These analyses establish that drug responses of primary glioblastoma cells can be associated to hallmark pathways and predicted with accuracy. The CV-R score of individual drugs (Table S2 and Discussion) is an indication of that drug's potential for use in specific GBM subpopulations, and several drugs with high CV-R remain to be investigated as GBM therapies (Discussion). The best drug response predictions for primary GBM cells were often based on multiple markers, often from two or more types of genomic data **(Figure S3A-B)**. Machine learning-based predictions were more accurate (higher CV-R on average) than corresponding predictions based on transcriptional subtype, clinical data, or mutation/expression of the drug target **(Figure S3D-E)**.

An axis of mutually exclusive TP53 and *CDKN2A/B* mutations in GBM

The association between drug response class and the p53 pathway motivated further analysis of genetic lesions in this pathway in our cell lines. Gliomas are known to have different lesions affecting the p53 core pathway, ranging from mutations affecting p53 itself to indirect de-regulation via amplification of *MDM2*, or deletion of the *CDKN2A/B* locus **(Figure 1C)**. The primary mechanism by which *CDKN2A/B* deletion affects p53 is through the loss of the CDKN2A gene product p14(ARF), a protein that blocks MDM2. Other gene products encoded by the *CDKN2A/B* locus are p16/INK4A and p15/INK4b, both of which block cyclin-dependent kinases (CDKs) (Tao and Levine, 1999).

To visualize genetic variation in the p53 pathway we applied a principal component analysis. Sorting our HGCC lines **(Figure 4A)** and TCGA **(Figure 4B)** along the first component of variation placed each case along an axis, defined by gradual changes in p53 pathway gene expression and mutual exclusivity between p53 mutation and *CDKN2A/B* deletion (Fisher's test p=0.0169 and p=6.4401e-05) **(Figure 4A,B)**. The analysis thus clarified that transcripts selected by our network algorithm **(Figure 3)** are mostly expressed in *CDKN2A/B* deleted cells with wild-type p53, and underlined that both cell cultures and surgical samples from gliomas can be categorized along a genetic and transcriptional axis, defined by mutually exclusive p53 and *CDKN2A/B*

aberrations.

To explore if this distinction was also observed at the protein level, we measured a 192 protein profile in two p53 mutated and two *CDKN2A/B* deleted cell lines, by multiplexed proximity extension assays. We found a significant correlation between RNA and protein expression differences ($p < 10^{-7}$) and noted p53 itself and the direct p53 target *CDKN1A* (p21) as the main differentially expressed gene products (**Figure 4C**). Consistent with a loss of p15 and p16, the *CDKN2A/B* deleted cultures expressed higher levels of two cyclin proteins, indicating that these cell lines also have a large population of cells with activated cyclin-CDK complexes committed to cell-cycle entry or mitosis (**Figure 4C**).

The p53-*CDKN2A/B* axis orchestrates the proteasome inhibitor response

Next, we asked how the observed variation in p53 and *CDKN2A/B* affects the response to proteasome inhibitors in GBM cells. Based on the above analysis (**Figure 4**) we selected a set of 10 HGCC cultures, with representative variation in the p53 gene signature, and with different mutation statuses of P53 and *CDKN2A/B* (Figure 5A). Among the 10, four were identified as p53 mutated by whole-exome and Sanger sequencing (Table S4), and three (U3054MG, U3173MG and U3180MG) were unable to induce p21 protein, confirming the loss of p53 function (**Figure S4B**).

To get a global overview of how cellular pathways are impacted by proteasome inhibition, we first compared the transcriptional response following bortezomib treatment (10nM, 6hrs) in one sensitive (U3013MG) and one resistant (U3180MG) cell line (**Figure 5B**). In both of the cell lines, proteasome inhibition induced unfolded protein response (UPR), ROS and p53 hallmark pathways in both lines and suppressed cell cycle promoting genes, but the resistant line showed a statistically stronger induction of genes involved in DNA damage response (DNA repair and ROS response) and in G2/M checkpoint regulators (**Figure 5B**). This suggested that resistant lines might differ in their ability to buffer ROS following proteasome inhibition, and in the activity of DNA repair pathways.

To explore these differences, we measured to what extent bortezomib-induced the level of ROS in each of the cell lines, as determined by the CM-H2DCFDA fluorometric assay as an indicator for ROS. Notably, the level of ROS induction was inversely proportional to the p53 signature (**Figure 5C**). The induction of ROS was also concomitant with elevated oxidized glutathione ratios (GSH/GSSG, **Figure 5D**), higher levels of Caspase-dependent apoptosis (**Figure 5E**) and accumulation of ubiquitinated protein in the sensitive lines (**supplement Figure S4C**), suggesting ROS-mediated apoptosis as a key effector mechanism (c.f. (Ling et al., 2003; Strauss et al., 2007)). Consistent with this hypothesis, blocking ROS by anti-oxidants protected cells against bortezomib, and elevating ROS by proteotoxic stress using heat shock aggravated the response (**Figure S4D**). A number of p53-dependent ROS-suppressive genes were induced selectively in the resistant cells, as determined by quantitative PCR, including *SESN1* (Budanov, 2011), *NFE2L2* (Ahmad et al., 2016) and *TIGAR* (Bensaad

et al., 2006), potentially explaining the effect **(supplement Figure S4A)**.

To assess differences in DNA repair, we stained two p53-mutant and two *CDKN2A/B* deleted cultures for 53BP1 protein following bortezomib treatment **(Figure 5F)**. We noted a significantly higher number of 53BP1 foci in resistant cell lines, both at basal levels and following 30 min bortezomib treatment indicating higher activity of the NHEJ DNA repair pathway (Unpaired two-tailed t-tests <0,0001 both at basal level and after treatment **Figure 5F,G**). Despite the induction of p21 protein in several of the cell lines **(Figure S4B)**, there were no signs of p21 induced G1 arrest. Rather, both the sensitive and resistant glioblastoma lines respond to bortezomib treatment by G2/M arrest **(Figure S5)**. The sensitive lines, however, reduced their S-phase population 2.9-3.1 fold as compared to 1.3-1.8 fold following 10nM bortezomib treatment **(Figure S5)** alongside an increased proportion of cells in apoptosis **(Figure 5E)**.

We conclude that in both p53 mutant and *CDKN2A/B* deleted glioblastoma cells, proteasome inhibition leads to G2/M arrest and ROS-dependent apoptosis. However, the quantitative balance between these outcomes is different, the more resistant cell lines are less prone to apoptosis, and show signs of lower ROS induction and higher DNA repair activity.

The TP53-CDKNA2/B axis determines *in vivo* bortezomib response

Next, we asked if the variation in p53 and *CDKN2A/B* aberrations would also affect the *in vivo* response to proteasome inhibition. To answer this, we evaluated 9 of the above cell lines in a transplantation based model of drug response, the chicken chorioallantoic membrane (CAM) assay (DeBord et al., 2018). Using GFP-luciferase tagged derivatives of each cell culture, we measured bioluminescence 3 days and 5 days post-inoculation onto the CAM **(Figure 6A)**. When grown on the CAM, treatment by the proteasome inhibitor bortezomib reduced the growth of some, but not all the primary GBM cultures, at concentrations that were tolerated by the chick embryo (5-10 µg/kg). The change in bioluminescence following proteasome inhibitor treatments agreed with the original drug screen results for the 9 cell lines (r=0.73, p=0.0189) **(Figure 6B)** and with the p53 gene signature score of the transplanted cell cultures (r=0.65, p=0.0419) **(Figure 6C)**. To explore these results in an independent model, we compared mice injected into the flank with a sensitive (U3013MG) and a resistant (U3008MG) cell culture showed significant (p=0.00682), reduction of tumor growth rate only for the former **(Figure 6E)**. These two experiments established that the variation observed in the initial drug screen was replicated *in vivo*.

Potentiating the proteasome inhibitor responses in glioma cells

Our observation that a subset of cell lines was less sensitive to proteasome inhibition motivated us to search for additional drugs that can be used to overcome proteasome inhibitor resistance. Pharmacologically, such drugs

should meet the criteria of synergism when combined with a proteasome inhibitor in glioblastoma cells. To explore this possibility, we selected a set of 25 drugs in different categories **(Figure 7A)** including (i) activators of p53, (ii) apoptosis modulators, (iii) kinase inhibitors against RTK and CDK pathways, (iv) compounds that were statistically selected based on their anti-correlation with bortezomib, (v) compounds that target redox regulation, and, (vi) compounds that target genes which are selectively upregulated in resistant tumors.

We evaluated each of the 25 drugs using the Combination Index (CI), estimated from a response surface over a 6x6 matrix of doses, replicated in 4-10 cell lines **(Figure 7B)**. Next, we evaluated if the average CI was less than 1.0 across all cell lines, thereby indicating that the compound consistently potentiates (i.e. is synergistic with) bortezomib **(Figure 7C)**. As a second endpoint, we performed a regression test to evaluate if CI depends on the p53 signature (example in **Figure 7D)**.

13 of the tested compounds potentiated bortezomib in multiple cell lines **(Figure 7E)**. Strong overall synergism was obtained with two p53 activators, the peptide-based MDM2 blocker PM2 (Spiegelberg et al., 2018) and the small molecule MDM2 blocker AMG232. By contrast, the mutant p53 selective reactivator PRIMA-1 showed selective single-agent activity in p53 mutant cells but did not potentiate bortezomib (**Figure 7E**, right column). Notably, all three apoptosis modulators potentiated bortezomib, as did the CDK2 inhibitor milciclib. This indicated that higher levels of wild type p53 protein or a lowered apoptotic threshold both suffice to potentiate bortezomib in primary glioblastoma cells. For 7 of the 13 potentiating compounds, a wild type p53 signature was associated with a lower CI value indicating stronger synergism **(Figure 7E)**. This shows that bortezomib can be potentiated especially in the more resistant type of cells with wild type p53 and *CDKN2A/B* deletion. One exception to this trend was mTOR inhibitor torin-2, which selectively potentiated bortezomib in p53 mutant cells, which may indicate a differential dependency on this pathway as indicated by our RNA profiling results (c.f. **Figure 5B**).

Interestingly, the three compounds selected in a purely data-driven fashion, by virtue of anti-correlation to bortezomib in Phase 2 and 3 screening data (the calcium channel blocker cilnidipine, the microtubule depolymerizing drug nocodazole, and the antibiotic spectinomycin) were all synergistic (**Figure 7E**, group iv). More studies would be required to elucidate the mechanism, but we speculate that a common denominator among all three might be the induction of unfolded protein stress. As an independent test of the synergies, we evaluated two of the selected combinations in a 3D sphere culture system (**Figure 7F**) and noted significantly lower viability in spheres treated by bortezomib and navitoclax or milciclib (**Figure 7G**).

In contrast to the consistent synergism for these drug classes, we found limited evidence that co-targeting redox pathways would potentiate bortezomib, e.g. NRF2 targeted agent costunolide (Ahmad et al., 2016) (not shown).

We conclude that both Bcl-2 family inhibitors and p53 activators show promise as potentiators of proteasome inhibitors in glioblastoma cells. Because the potentiating effect is stronger in *CDKN2A/B* deleted (often more bortezomib resistant) cell lines, the results suggest a strategy to target also these cells. We also find signs that

automatically nominated compounds, selected by virtue of their anti-correlation in the screening data, make good combination partners.

Drug classes and targets with high prediction scores

Discussion

The goal of our study was to identify new opportunities for GBM precision medicine, by an integrated study of patient-derived GBM cells. Previously, an initial set of 48 glioma cell cultures has been distributed as the Human Glioma Cell Culture (HGCC) resource (Xie et al., 2015).Extending this collection to 100 cell cultures, characterised at multiple genomic and functional levels, enabled us to map the association between pathways and multiple drug classes. The resulting data thus provide a starting point for research investigating drug repurposing and precision therapy.

As a validation of our resource, we investigate the detected association between mutually exclusive aberrations in p53 and *CDKN2A/B* and the sensitivity to several proteasome inhibitors. The impact of mutations in the tumor suppressor p53 and *CDKN2A/B* loci on the efficacy of proteasomal remains to be fully understood. On the one hand, p53 is identified as one major mechanism underlying the effect of proteasome inhibitors because proteasome inhibition can induce apoptosis through stabilization of p53 protein (Xue et al., 2019). On the other hand, proteasome inhibitors can also be highly effective against p53 mutant cell lines of various tissue origins, such as glioma (Seol, 2011), epithelial carcinomas (Dabiri et al., 2017; Adams et al., 1999; **?**; Qiang et al., 2017), blood malignancies (Strauss et al., 2007; Hideshima et al., 2001). Suggested mechanisms for this include p53-independent induction of p73 (Dabiri et al., 2017), and induction of apoptosis regulating proteins such as DR5 (TRAILR2) (Qiang et al., 2017; **?**). Of the 10 cell lines that we investigated in detail, 7 had signs of functional p53, indicated by their ability to induce p21 after genotoxic stress. Less is known about of how *CDKN2A/B* deletion affects proteasome inhibitor response, but since it is established that proteins encoded by the locus (e.g. p16/INK4A) are modulated by the proteasome pathway, such effects are plausible. Taking these factors into account, the model we propose for the relative resistance to proteasome inhibitors in some GBM cell lines is that the level of p53 activation stays under a threshold, insufficient to induce apoptosis. This could be dependent on the increased synthesis of anti-oxidants, e.g. glutathione (**Figure 5D**) that scavenge reactive oxygen species and more active DNA damage repair mechanisms in the proteasome inhibitor-resistant cell lines (**Figure 5F,G**). Consistent with the proposed model, MDM2 inhibitors PM2 and AMG232 potentiated the bortezomib response and synergistically killed GBM cells, and all three agents that modulate the apoptotic threshold, such as navitoclax, potentiated bortezomib. Our results are thus consistent with a role for p53 in the response to proteasome inhibitors, in line with (**?**Asklund et al., 2012; Forte et al., 2019) but imply substantial quantitative and phenotypic differences in the response to proteasome inhibition. Further work, including

quantitative mathematical modeling, will be needed to elucidate these differences and to chart the relative contributions of aberrations in p53 and *CDKN2A/B*, respectively.

The clinical potential of the reported gene signature and combinations remains to be assessed. Among the publicly disclosed proteasome inhibitors, salinosporamide A (Marizomib) shows promise for CNS tumors, as it penetrates the blood-brain barrier in rodent models (Di et al., 2016) and is under phase 3 investigation in humans (NCT03345095). Our proposed classification of glioma cells based on p53 and *CDKN2A/B* status has potential applications in the prospective design and post-hoc interpretation of proteasome inhibitor clinical trials in GBM. Notably, germline mutation of both p53 (Li-Fraumeni syndrome) and CDKN2A (melanoma-astrocytoma syndrome) are associated with substantial risk increase for brain tumors. We speculate that the small group of patients with a GBM associated with Li Fraumeni syndrome might be a particularly interesting group for proteasome inhibitor treatment. The identified combinations provide a framework to study the potentiation of proteasome inhibitors. While many of the detected effects are robust across cells from multiple patients (particularly for Bcl-2 family inhibitors), more analysis is warranted to assess the efficacy and safety of such combinations.

In addition to the specific observations related to proteasome inhibitors, our analysis gives interesting general insights regarding GBM precision therapy. First, we note that the established subtypes (proneural, classical, and mesenchymal) are relatively weak predictors of drug response, compared to the optimally selected transcriptional or genetic markers. Also, the best performing biomarkers are not necessarily somatic point mutations, motivating the use of multiple data layers as a strategy to identify biomarkers for drug response in GBM cells **(Figure S3)**. Second, the range of drugs whose response can be predicted with accuracy in primary GBM cells is broader than frequently investigated kinase inhibitors (*c.f.* **Table S3)**. Drugs with high predictive performance (high CV-R) and strong effect (low AUC) in a subset of cell cultures are of particular interest for drug repurposing. Key examples of such drugs in our atlas include calcium modulators (digoxin, calcimycin (A23187) and niguldipine), three likely anti-metabolites (lycorine, thioguanosine, perhexiline), an anti-malarial (quinacrine), modulators of dopaminergic transmission (sertindole, 5-nonloxytryptamin), antiseptics (hexetidine, chlorhexidine, ciclopirox), and the cyclical peptide thiostreptone, all with high ranking CV-R scores **(Table S2)**. Accordingly, we propose that the proteins and pathways targeted by these drugs may warrant further investigation as candidates for stratified therapy of GBM. For instance, quinacrine is a known inhibitor of phospholipase A2 (PLA2), an enzyme that hydrolyses phospholipids into second messengers that regulate cell proliferation, cell migration and cell survival through binding of G-protein coupled receptors (**?**). High expression of PLA2 has been associated with poor prognosis and therapy resistance in glioma patients (**?**), (**?**). As a second, example, the activity of digoxin and digitoxigenin may imply Na+ -K+ ATPase (ATP1A1) as a possible target in GBM, or other targets affected by digoxin drugs in GBM cells, such as HIF1alpha and HIF2alpha (**?**). Last, we note that more than 80% of the GBM cultures are sensitive to omacetaxine mepesuccinate (homoharringtonine), a blocker of the large 60S ribosomal subunit peptidyltransferase center (**?**), with

RPL3 as the possible target (**?**), suggesting that ribosomal function or biogenesis may be promising targets in subsets of GBM. Continued integrated analysis of primary cell lines, linked to in vivo assessment, will likely broaden our perspective on GBM precision therapy even further.

The presented extension of the HGCC biobank presents a valuable resource for GBM precision medicine, distributed as an open-access cell line library (hgcc.se) with associated databases (portal.hgcc.se) and networks of biomarker-drug associations, which can be analyzed in Cytoscape (Shannon et al., 2003) or compatible programs. Users are invited to explore the data and retrieve primary GBM cell lines with known genomic parameters or drug sensitivity, for functional studies, or for data-driven modeling. Building on early successes with heterogeneous traditional cell lines (Kutalik et al., 2008; Barretina et al., 2012; Garnett et al., 2012; **?**; Basu et al., 2013; Seashore-Ludlow et al., 2015; Iorio et al., 2016), we expect that an increasing number of well-characterized and diagnosis-specific data sets will gradually increase both the predictive power, interpretability and clinical relevance of cell line panels.

Acknowledgements

Author Contributions

The study was conceived by SN and coordinated by CK. The multi-omic profiling was performed by SB, LE and analyzed by PJ, SN. The drug screen was performed by SB, LS, LE, MH, UM, BL. The integrative analysis was performed by PJ, SN. The experiments in Fig 4 were designed and performed by SK, CK, EA, SB, LS, LE, CG, MF, RE. Additional biobank characterisation by LU, FS. The CAM and mouse experiments were designed and performed by MD, AH, PS and CK, SK, respectively. CV and SM performed the prospective tests of proteasome inhibitor sensitivity. SL, MN, and DL contributed the analysis of p53-independent apoptosis and p53 activators. The manuscript was written by SN, PJ and CK and finalized with contributions from all authors.

Declaration of Interests

The authors declare no competing interests.

Main Figure Titles and Legends

Figure 1: Study overview and genomic characteristics of primary GBM cultures

(A) Study overview. Based on the integrated profiling of 100 patient-derived GBM cultures, we here develop network models of drug response, which identify p53 as a key determinant of pharmacological class.

(B) Cohort composition compared to the TCGA; age distribution, sex, survival and transcriptional subtype.

(C) Alterations frequencies of key genes in the p53 and RTK/MAPK pathways, arranged as in (Brennan et al., 2013) Note the similarity between primary GBM cultures and TCGA surgical samples across core GBM pathways (R=0.82). (Red indicates amplification or mutation, blue indicates deletion or mutation.)

Figure 2: Defining the global variation of drug response in primary GBM cells.

(A) Structure of the screen. A 1544 drug discovery screen (phase 1) was followed by secondary and tertiary screens across using focused libraries of drugs with GBM activity (phase 2 and 3). Drugs in our phase 2 library had 363 known targets, 75 of which were over-represented (empirical p-value less than 0.05) compared to the phase 1 library, e.g. EGFR, PDGFRA/B (bars).

(B) Drug target annotation of our GBM library, in comparison to recent studies of cancer cell panels. Mechanism-of-action (MOA), disease indication and target from the Drug Repurposing Hub database.

(C) Two-way clustering of primary GBM cultures (rows) and drugs (columns) based on Area Under the dose-response Curve (AUC) scores. The GBM cultures were robustly grouped into two clusters that did not correlate with transcriptional subtype. The drugs were grouped into more than 10 clusters, many of which were enriched for drugs with a shared target (selected targets discussed in the text).

(D) The AUC of the 6 proteasome inhibitors in our library was markedly bimodal (dashed box) and consistent across compounds, here shown as dose-response curves.

Figure 3: Network analysis links proteasome inhibitors to the p53 pathway

(A) Drug response in primary GBM cultures correlates, in a drug mechanism-dependent manner, with the transcriptional activity of specific pathways. The network describes statistically supported (p<0.05) associations between drug mechanism-of-action (MOA, green circles) and Hallmark pathways in the Molecular Signature Database (grey boxes). Nodes sizes are proportional to the number of involved drugs and genes, respectively and line thickness is proportional to $-log10(p-value)$ of the association. The MOA nodes are color-coded (dark green - yellow) based on their average predictive power (CV-R) (c.f. Table 1).

(B) Machine learning detects biomarkers of proteasome inhibitor response in GBM. The algorithm (bootstrap elastic net regression) detected a combination of mutations, CNAs, DNA methylation events and transcripts predictive. Selected transcripts were members of the p53 Hallmark pathway.

(C) The machine learner predicted proteasome inhibitor response in GBM cells from unseen patients. Bar chart: predicted viability in 20 primary GBM lines from a different hospital (Queen Mary, London). Lines predicted

to be sensitive (GBM54) and resistant (GBM19) were confirmed in a separate dose-response experiment.

Figure 4: Aberrations of p53 and *CDKN2A/B* in cell lines and patient samples.

(A) HGCC cultures ordered according to the 1st principal component of the p53 pathway (Methods). Note the mutual exclusion of p53 and *CDKN2A/B* aberrations

(B) TCGA surgical samples ordered according to the corresponding 1st principal component.

(C) Differential expression of RNA (y-axis) and protein (x-axis) for 192 genes/proteins, comparing 2 sensitive vs 2 resistant lines.

Figure 5: Cellular effects of bortezomib treatment in a sample of GBM cells

(A) Sample of cell lines for in-depth functional analysis. The p53 status gradient indicates the first principal component of the p53 signature. The grey boxes indicate the presence of p53 mutations, *CDKN2A/B* deletion, and p21 protein expression (see Supplemental figure S4A).

(B) RNA profiling comparison of one sensitive and one resistant line, measuring the log fold change of transcripts after 10 nM bortezomib for 6 hrs. Enrichment analysis of commonly affected (average fold change in both lines) pathways and differentially affected (fold change difference) pathways. Fisher's test with FDR correction.

(C) P53 signature predicts ROS response. X-axis: p53 signature principal component score as in Figure 4A, Y-axis relative increase (a.u.) of ROS as measured by a fluorometric assay (linear regression, $R^2=0.58$, $p=0.0105$).

(D) Redox balance (GSH/GSSG ratio) and (E) apoptosis in bortezomib resistant (n=5) vs sensitive (n=5) patient-derived GBM cultures. Mann-Whitney U test.

(F) Comparison of induction of 53BP1 NHEJ DNA double-strand break processing and repair in 4 lines by bortezomib.

(G) Quantification of 53BP1 foci illustrated in (F). Student's t-test.

Figure 6: The p53/CDKNA2/B axis determines *in vivo* responses and predicts tumor initiation.

(A) The chorioallantoic membrane (CAM) *in vivo* assay was used to measure the response to bortezomib in 9 patient-derived cell lines.

(B) Correlation of CAM result and *in vitro* AUC viability score. X-axis: average proteasome inhibitor AUC from the drug screen. Y-axis: negative values indicate a stronger reponse to bortezomib treatment.

(C) Correlation of CAM result (y-axis) and p53 signature score (x-axis, defined as in Figure 4A).

(E) Tumor growth rate of flank xenografted sensitive (U3013MG, CDKN2A wt, p53 mut) vs resistant (U3008MG, CDKN2A del, p53 wt) GBM cells in immune deficient mice, showing a selective bortezomib effect in tumors from sensitive cells.

Figure 7: Modulation of proteasome inhibitor response of glioma cells.

(A) Based on our integrated data, we tested 25 compounds in combination with a proteasome inhibitor.

(B) Each compound was evaluated across a 6x6 dose-dose-response surface, replicated in multiple cell lines

with different p53 signature scores.

(C) Combination Index statistics for 25 compounds. X-axis: compounds. Y-axis: statistical spread of CI for tested patient-derived cell lines. Points are individual patient-derived cell lines, boxes are 90% confidence intervals.

(D) Test for CI dependency on p53 signature, two linear regression examples, indicating a lower CI for a higher value of the p53 signature score.

(E) Summary; significant results for endpoint 1 (average CI < 1.0) and endpoint 2 (CI depends on p53 signature) are shaded. Arrows indicate a positive (up) or a negative (down, as in (C)) dependency on the p53 signature.

(F) Sphere model to evaluate bortezomib in combination with navitoclax in one bortezomib-sensitive (U3013MG) and one resistant line (U3008MG). Bars = 800 μ. (G) Sphere size is significantly affected by bortezomib and navitoclax treatment. Red bar = observed sphere size after combination treatment. Dashed bar = expected sphere size after combination treatment, based on an additive model. Bars are 90% confidence intervals.

STAR Methods

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Tumor sample collection was approved by the Uppsala regional ethical review board, number 2007/353; informed consent was obtained from all subjects included. The cell line designations and key data (sex, age, survival) of each subject are listed in Table S1.

METHOD DETAILS

Cell culture collection methods

Primary cultures were derived from tumor samples in defined serum-free neural stem cell (NSC) medium, supplemented with B-27, N2, EGF, FGF, on laminin-coated Corning™ Primaria™ Cell Culture plates (Thermo Fisher Scientific, Waltham, MA) as described (Xie et al., 2015), and GBM cells (Table S1) were subsequently grown in this medium. The cell cultures for the drug screening assay were between passage 8 and 24 (average 16). As reference cell lines, we used human immortalized astrocytes (Arne Östman, Karolinska Institutet), HepG2 (Bo Lundgren, Stockholm University) and human foreskin fibroblasts 1523 (Karin Forsberg

Nilsson, Uppsala University). References cells were grown as adherent cultures in DMEM culture medium (Invitrogen, Carlsbad, CA) supplemented with 1% L-Glutamine (Sigma-Aldrich, St. Louis, MO), 1% Penicillin/Streptomycin (Sigma-Aldrich), 1% Gibco MEM Non-Essential Amino Acids (Thermo Fisher Scientific) and Gibco 10% fetal bovine serum (Thermo Fisher Scientific). H9-derived human neural stem cells, propagated as adherent culture in complete StemPro® NSC SFM (A1050901, Thermo Fisher Scientific) according to manufacturer instructions were also included as a reference.

Genomic profiling of patient-derived GBM cultures

Genomic profiling of the GBM cell lines (Figure 1C, Figure S1) was conducted at Science for Life Laboratory core facilities (scilifelab.se) and the Uppsala Academic Hospital Array and Analysis facility. DNA was amplified from cell lines using the DNeasy Blood and tissue kit, Qiagen. DNA copy number aberrations were measured using Affymetrix Cytoscan HD arrays (Thermo Fisher Scientific) in accordance with the manufacturer's instructions (Affymetrix® Cytoscan User Guide (P/N 703038 Rev4.). Chromosomal segments carrying altered numbers of copies was estimated using the Patchwork R package (Mayrhofer et al., 2013), which quantifies the log-relative change in DNA content for each chromosomal region. DNA whole exome sequencing of cell lines was performed using Ion Torrent sequencing as follows. 100 ng of genomic DNA, amplified according to Ion AmpliSeq™Exome Library Preparation protocol (Thermo Fisher Scientific). Adaptors (Ion P1 Adapter and Ion Xpress™Barcode Adapter, Thermo Fisher Scientific) were then ligated to generate sequencing libraries, which were purified using Agencourt® AMPure® XP reagent (Beckman Coulter) and eluted in amplification mix (Platinum® PCR SuperMix High Fidelity and Library Amplification Primer Mix, Thermo Fisher Scientific) and then amplified. Size-selection and purification was conducted using Agencourt® AMPure® XP reagent (Beckman Coulter). Emulsion PCR was performed on the Ion OneTouch™2 system using the Ion PI™Template OT2 200 Kit v3 (Thermo Fisher Scientific). Samples were loaded on Ion PI™chips v2 and sequenced on the Ion Proton™System using Ion PI™Sequencing 200 Kit v3 chemistry (Thermo Fisher Scientific). Data were analyzed and with the Torrent Suite Software (Thermo Fisher Scientific). Following alignment to the hg19 reference genome using BowTie, we computed somatic variants using Torrent Suite, SomaticSniper (Larson et al., 2012), VarScan2 (Koboldt et al., 2012) and MuTect 2 (Cibulskis et al., 2013) using default settings. We annotated the variants using ANNOVAR (Wang et al., 2010) and dbsnp138 (https://www.ncbi.nlm.nih.gov/projects/SNP/). The calls were aggregated across the four callers and a gene was considered mutated (1) if it met the criteria of (i) being found by at least 3 callers, (ii) was annotated as nonsynonymous, and (iii) not present as germline variants in the 1000 genomes project (1000 Genomes Project Consortium et al., 2015) above 2 percent prevalence according to ANNOVAR. DNA methylomes were measured on Infinium® MethylationEPIC BeadChip Infinium arrays (Illumina, San Diego, CA), in accordance with the Infinium® HD Assay Methylation protocol (Illumina). Quality control of the generated data was performed using the methylation module of the GenomeStudio® v2011.1 data analysis software (Illumina) and by

use of the BeadArray Controls Reporter software (Illumina) to analyze the sample controls. From the primary data, probe specific β values, for 850,000 probes were computed as the probe-specific methylation fraction. RNA profiling was performed using Affymetrix HTA 2.0 arrays according to manufacturer recommendations, normalized to gene level using the Affymetrix Power Tools version 1.19.0 (http://www.affymetrix.com). The resulting gene expression data were normalized using the naiveReplicateRUV method (Gagnon-Bartsch and Speed, 2012) with negative control genes defined as in (Eisenberg and Levanon, 2003).

Pharmacological profiling of patient-derived GBM cultures

Large-scale measurements of drug responses (Figure 2) were carried out at the Science for Life Laboratory Drug Discovery and Development platform. Cells were seeded one day prior to treatment using a Multidrop 384 liquid dispenser (Thermo Fisher Scientific) in laminin-coated 384-well microplates (BD Falcon Optilux #353962), at a density ranging from 2000-4000 cells per well to ensure subconfluent growth phase (approximately 70%) at the end of the assay. For the initial screen in 9 glioblastoma cell cultures (Figure 2A) we tested 1544 unique compounds from the Screen-Well® kinase inhibitor library (BIOMOL International/Enzo Life Sciences, Plymouth Meeting, PA, 80 compounds), the NCI DTP Repository (National Institute of Health, Rockville, MD, 101 compounds), the NIH clinical collection (https://commonfund.nih.gov/molecularlibraries/tools, 727 compounds), and the Prestwick Chemical Library® (Prestwick Chemical, San Diego, CA, 1200 compounds). Redundant compounds were removed to a total of 1544 compounds. In the subsequent screen (c.f. Figure 2A) 262 compounds were tested in 11-point dose dilution series (starting at 100µM in Phase 2 and 50µM in Phase 3) and assayed for viability after 3 days of treatment using a Resazurin assay diluted 1:10 in medium as previously described (Page et al., 1993), and detected by a fluorescent plate reader (EnVision multilabel reader, PerkinElmer). Each plate was subject to quality control comparing fluorescence values of doxorubicin treated (11 doses, 0-100 µM) cells as positive control and DMSO vehicle (0.1%) as negative control. All data was normalized against plate DMSO vehicle wells. We scored the sensitivity of each cell culture to each compound by an Area Under the Curve (AUC) score for the dose-response values. This metric was used since it gives an interpretable value for all drugs and cell cultures, not only for those with well-defined IC50. For 183/262 compounds, the IC50 was within the 11 dose range and for an additional 16 drugs, the IC75 was within the dose range used (Table S2).

Functional validation of p53-dependent responses of GBM

Gene signature of p53 activity in GBM, and analysis of p53 status in 10 GBM cultures

For all GBM cultures with available whole-exome sequencing and RNA profiling data (n=62) we computed the differential expression between p53 mutant and p53 wild type cell cultures, detecting p53 as the main differ-

entially expressed pathway. The 36 transcripts in the p53 Hallmark pathway that were differentially expressed (BH adjusted p<0.05) were arranged as a matrix, which was analyzed by PCA, whereby the first principal component was used as the p53 signature score of each cell culture (Figure 4A). We selected 10 representative GBM cultures based on variation in this p53 signature and proteasome inhibitor response (Figure 5A). To confirm p53 status, we used targeted Sanger sequencing (c.f. . For each of the 10 selected cultures, we amplified DNA sequences for p53 coding exons as described by Pfaff et al., (Pfaff et al., 2010). The sequencing was performed as Light run in forward direction by GATC Biotech (Konstanz, Germany) using 5 µl of PCR products and sequence alignment was carried out using the SnapGene Viewer 4.1.9 software (GSL Biotech LLC, Chicago, IL) against the NC_000017.11 TP53 reference sequence. The International Agency for Research on Cancer TP53 database (http://p53.iarc.fr/) was used to determine the significance of identified sequence variants. As a complement to Sanger sequencing, p53 functional status was assessed using an etoposide treatment assay (Figure S4B), as follows. The selected 10 GBM cell cultures were treated with 10 µM etoposide for 2, 6, 16 and 24 hrs, following lysis in RIPA buffer (Thermo Fisher Scientific) supplemented with cOmplete™ULTRA protease inhibitor cocktail (Roche, Basel, Schweiz) and phosphatase inhibitors PhosSTOP (Roche). 25 microgram of lysate was resolved by 4-12% Bis-Tris gradient gel (Invitrogen) in MOPS buffer, transferred onto nitrocellulose membranes (Invitrogen) and blocked in buffer (5% (wt/vol) BSA or 5% (wt/vol) nonfat milk (Bio-Rad) , TBST (TBS, pH 7.4, 0.1% Tween-20) for 1 hr at room temperature. Primary antibodies used were p21 rabbit antibody (12D1, Cell Signaling Technology) (1:1000 in 5% BSA, TBST), beta-actin mouse monoclonal antibody (C4, Santa Cruz) (1:1000 in 5% milk, TBST) and cyclophilin rabbit polyclonal antibody (ab16045, Abcam) (1:2000 in 5%milk/TBST). Following overnight incubation of membranes with primary antibody at 4°C. HRP-linked secondary antibodies were diluted in blocking buffer; donkey anti-rabbit (GE Healthcare, Chicago, IL) (1:5000 in 5% BSA), goat anti-mouse (GE Healthcare) (1:5000 in 5% milk), and incubated for 1 hour at room temperature. Blots were developed by Amersham™ECL Select™ western blotting detection reagent (GE Healthcare), and visualized using ImageQuant LAS 4000 (GE Healthcare) biomolecular imager.

RNA profiling and GSEA

For Figure 5B, we used RNA sequencing using the method in (Almstedt et al., 2020) to profile U3013MG and U3180MG cells after 6 hrs treatment by bortezomib, marizomib and delanzomib at 10nM (n=3 technical replicates for each treatment). Vehicle treated cells were used as replicates (n=3 technical replicates). We used Fisher's test with FDR p value correction to test for overlap between Hallmark pathways and genes that were either upregulated in both cell lines (average fold change in both) or selectively up in U3180MG vs U3013MG (fold change in U3180MG cells minus the fold change in U3013MG cells).

Responses to proteasome inhibition in 10 GBM cultures with different p53 status

To measure the effects of proteasome inhibition, we used qPCR, western blot and proximity extension assays as follows. For Figure S4A, we selected a panel of genes for qPCR validation. Selection was based on whether (i) they were a marker in our network analysis, (ii) they were a known p53 target or (iii) involved in other key pathways. 10 GBM cultures were seeded into 6 well plates and were treated with DMSO vehicle or 10 nM Bortezomib A panel of 10 GBM cultures with different proteasome inhibitor sensitivity were treated with 10nM bortezomib (PS-341, #S1013, Selleck Chemicals, TX, USA) or vehicle (0.1% DMSO) for 6 hrs and 24 hrs in triplicates. Total RNA was isolated using the phenol/chloroform method with TRIzol LS Reagent (#10296010, Thermo Fisher Scientific) and 500 ng of total RNA was then transcribed using iScript^{TM} gDNA Clear cDNA Synthesis Kit (Bio-Rad, Hercules, CA, US) and diluted in sterile water to a concentration of 1.875 ng/µl. Quantitative PCR was carried out on a CFX384 Touch^{TM} Real Time PCR Detection System (Bio-Rad), using SsoAdvanced^{TM} Universal SYBR™Green Supermix (#1725275, Bio-Rad) in duplicates in a total reaction volume of 10 µl, using primers in (Table S5). Gene expression was normalized using 3 reference genes (RPS18, GAPDH, RLP13A) and calculated with qBase MSExcel VBA applet (Hellemans et al., 2007). To analyze protein turnover in treated vs untreated resistant and non-resistant cells (Figure S4C), we analyzed detergent soluble and insoluble fractions, for enrichment of aggregated protein (Miyahara et al., 2016; Moriya et al., 2015) after 24 hours of bortezomib treatment, by western blot detection of ubiquitin (P4D1, Cell Signaling Technology, Inc., Danvers, MA, 1:1000 in blocking buffer) with b-actin (C4, Santa Cruz, Dallas, TX, 1:10000 in blocking buffer) as a loading control. Blots were developed and visualized as described above. To quantify glutathione ratios and caspase activity following bortezomib treatment **(Figure 5D, E)**, we used the GSH/GSSG-Glo and Caspase-Glo 3/7 assays (Promega, Madison, WI) respectively. Proteome alterations were measured on proximity extension assay (PEA) arrays (Olink Proteomics, Uppsala, Sweden), using two panels targeting proteins involved in cancer-related pathways and cellular processes. Each PEA panel included 192 assays targeting proteins and four spike-in controls consisting of two recombinant non-human proteins as incubation controls, an extension control, and a PCR detection control. We used log fold change values to search for proteins changed by proteasome inhibition in resistant and non-resistant cells and to compare levels of proteins and corresponding mRNAs in untreated cells **(Figure S4E)**.

Details of Proximity Extension Assay Analysis

Cell cultures U3013MG, U3054MG, U3008MG, and U3213MG were seeded at 15,000 cells per well in two replicate 96-well plates [Greiner Bio One cat#655986]. Twenty-four hrs later, bortezomib was added at a final concentration of 1 nM, 6 nM, 10 nM or 0.2% DMSO as vehicle control. At 24 hrs post-drug exposure, the replicate plates were gently washed 1X with PBS (37°C). Subsequently, the cells in one 96-well plate were fixed at room temperature for 10 min with a mixture of 2% PFA, 0.1% Triton X-100 and 10µg/ml Hoechst stain. The

fixed cells were to enumerate the number of cells per well per corresponding treatment regimen. The cells in the second plate were lysed with 25μl ice-cold lysis buffer/well (1% NP-40, 0.1% Triton X-100, 0.1% sulfobetaine, 150 mM NaCl, Protease Inhibitor Cocktail cOmplete™mini (Roche), TE pH 8). Following the addition of the lysis buffer, the plate was briefly vortexed, centrifuged for 1 min, 4°C at 1000 rpm, and then stored at -80°C until use. The cell lysates were analyzed for relative protein expression using two non-commercial, exploratory multiplex proximity extension assay (PEA) panels (Olink Proteomics). The two panels target proteins involved in cancer-related pathways and cellular processes (e.g. cell cycle) respectively. Each PEA panel includes 92 assays targeting proteins and four spike-in controls consisting of two recombinant non-human proteins as incubation controls, an extension control (ExtCtl) and a PCR/detection control. Briefly, 2μl cell lysate was mixed with 3μl multiplex PEA probe mix. The mix contained 0.3μl of each the PEA A- and B-oligonucleotide conjugated antibody probes (final antibody-conjugate concentration of 100 pM), 0.2μl Incubation Stabilizer (Olink Proteomics), and 2.1μl Incubation Solution (Olink Proteomics). Each analysis plate included 8 replicate lysis buffer-only negative controls. The plates were briefly centrifuged, sealed, and incubated overnight at 4°C. Following overnight incubation, plates were briefly spun down, and 96 ml of a PEA probe extension mix was added to each well. The mix contained 0.2μl PCR Polymerase, 0.5μl PEA Enzyme, and 10μl PEA Solution (all Olink Proteomics) and 85.3μl molecular grade water. Plates were sealed, gently vortexed, spun down, and then placed in a thermal cycler for the extension reaction (50°C, 20 min) and pre-amplification of extended PEA probes via universal primers (95°C, 5 min; 95°C, 30 s; 54°C, 1 min; and 60°C, 1 min) for 17 cycles. The pre-amplified DNA molecules from the multiplex detection reaction were decoded and quantified using a Fluidigm 96.96 Dynamic Array Integrated Fluidic Circuit on a Biomark HD system. 2.8μl of each sample was mixed with 5μl Detection Solution, 0.071μl Detection Enzyme, and 0.028μl PCR Polymerase (all Olink Proteomics) and 2.1μl molecular grade water. 5μl of each sample plus detection mix was loaded into a primed 96.96 Dynamic Array IFC (right inlets). 5μl of each of the 96 primer pairs (Olink Proteomics), designed to amplify individual target-specific DNA reporter sequences generated in the PEA reactions, was also loaded in the Dynamic Array (left inlets). The chip was placed in Fluidigm's IFC HX according to the manufacturer's instructions and then run in Fluidigm's Biomark with the following settings (Gene Expression application, ROX passive reference, single-probe assay with FAM-MGB probe) and protocol: thermal mix (50°C, 120 s; 70°C, 1,800 s; 25°C, 600 s), hot start (95°C, 300 s), and PCR cycling for 40 cycles (95°C, 15 s; 60°C, 60 s). BioMark generated PEA output files were processed to flag data points where the ExtCtl was smaller or greater than two standard deviations from the ExtCtl sample mean. The remaining Ct values were normalized as follows: for each sample, the Ct value of the ExtCtl was subtracted from the Ct value of the protein analyte yielding dCt values. Then, for each assay, the dCt values were subtracted from a negative control background value computed as the mean - 3*SD of the lysis buffer only negative control values. This ensures that observed signals for each assay in the presence of a cell are at least 3 standard deviations away from any signals observed in the absence of any antigen. All resulting values below zero were set to zero, and the signal was deemed undetected. The data are presented in (Figure 4C, S4E).

p53 targets and ROS levels in proteasome inhibitor-treated GBM cultures

To measure the level of reactive oxygen species before and after treatment **(Figure 5C)**, we seeded GBM cells to Corning 96-well black wall plates at the concentration of 10.000 cells per well in NSC medium where B27 supplement was replaced with B27 Supplement, minus antioxidants (10889-038, Thermo Fisher Scientific). After overnight incubation, cells were treated with etoposide (10, 30 and 50 μM) and bortezomib (10 nM) for 30 hrs. For assessment of general reactive oxygen species, cell-permeant fluorescent probe CM-H2DCFDA (#C6827, Thermo Fisher Scientific) was used at 2.5 μM final concentration, and cells were imaged by an IncuCyte® S3 live-cell imaging system (Sartorius, Göttingen, Germany) (10x objective, 3 biological replicates x 4 technical replicates). Acquired images were analyzed with the IncuCyte® inbuilt software to determine average green mean object intensity (GCU). The experiment was performed in three biological replicates in a panel of ten GBM cell cultures.

Glutathione ratio and Caspase 3/7 assays.

We measured bortezomib-induced cellular stress (Figure 5D) using the luminescence-based GSH/GSSG-Glo assay (Promega). Both oxidized and total glutathione levels were obtained and used to calculate the ratio of reduced to oxidized glutathione. Cells were seeded at 5,000 cells/well. After 24 hours, cells were treated with either the drug bortezomib at 10 nM or the vehicle for 72 hours. Triplicate wells were used per condition. Luminescence was measured following the manufacturer's instructions, and background values were subtracted from all measurements. The ratios of GSH/GSSH were calculated for vehicle and control-treated cells. To measure Caspase 3/7 activity (Figure 5E), cells were seeded overnight at 5,000 cells/well in laminin-coated 96-well Primaria plates in standard NSC medium. Cells were then incubated for 48 hours with bortezomib (10 nM), the corresponding DMSO concentration, or left untreated. Triplicate wells were used per condition. Viability assay was performed using the alamarBlue® cell viability reagent. Measurement of caspase 3 and 7 levels was performed using the Caspase-Glo® 3/7 Assay detection assay kit (Promega) following manufacturer recommendations. As above, cells were seeded overnight in a white-walled 96-well plate at 5.000 cells/well following incubation for 48 hrs in triplicate with bortezomib (10 nM), vehicle or left untreated. An equal volume of reconstituted Caspase-Glo Reagent was added to each well and luminescence was measured after 30 min incubation. Background luminescence was subtracted. The amount of Caspase 3/7 was then calculated relative to cell viability for each cell culture.

In vivo validation of differential proteasome inhibitor responses in GBM

Chicken chorioallantoic membrane assay

For Figure 6A-C, fertilized White Leghorn chicken eggs were obtained within a week after laying (LSK Poultry Oy, Laitila, Finland). The highest non-toxic dose of bortezomib was established to be approximately 10 µg/kg. On EDD 7, $1x10^6$ glioblastoma cells were transplanted onto the CAM in 20 µ50% Matrigel^{TM} (#11543550, Fisher Scientific) and PBS suspension (Supplement). On EDD 10, we recorded bioluminescent (BLI) signal using an IVIS Spectrum camera (PerkinElmer) and applied vehicle (0.01% DMSO) or bortezomib (5 or 10 µg/kg) topically on the CAM. On EDD 12, IVIS imaging was repeated and embryos were euthanized. BLI signal was analyzed using Living Image 3.2.0 (PerkinElmer) software and we used linear regression to estimate the log fold IVIS signal per µg/kg unit of treatment, with data from n=322 eggs in total.

Mouse xenotransplantation and bortezomib treatment

All mouse experiments were performed in compliance with an ethical permit granted by the Uppsala Animal Research Ethical Board, number C41/14. 7 week-old Balb/cAnNRj-Foxn1nu/Foxn1nu female mice (Janvier Labs, Le Genest-Saint-Isle, France) were injected with U3013MG cells cultured adherently, U3013MG cultured as spheres and U3008MG cultured as spheres. When tumor volume exceeded 0.1 cm^3, mice were randomized into groups treated with bortezomib (0.5 mg/kg; n=14) or vehicle (DMSO; n=8). After tumor induction with PI-sensitive and PI-resistant glioblastoma cell cultures, mice were monitored at least twice per week. Weights were taken once per week initially and three times weekly once tumors developed. Tumors were measured three times weekly by caliper and tumor volume was calculated according to (length x width^2)/2. Treatments were administered twice a week by intraperitoneal injection. All animals were euthanized once the tumor volume reached 1000 mm ^{3} or after a maximum of 4 weeks of treatment. In the analysis, mice injected with adherently and sphere grown U3013MG were pooled and data was analyzed using a linear mixed-effect model, with data from n=22 mice in total (statistics section, below) (Figure 6E).

Validation of functional associations and synergistic drug combinations

Modulation of proteasome inhibitors by heat, antioxidants and potentiating drugs

To measure whether antioxidants or heat-induced accumulation of ROS could have a protecting or potentiating effect in bortezomib treated GBM cells, we analyzed their viability in drug pair combination assays. Primary GBM cultures were treated by vehicle, bortezomib (10nM), or combination of bortezomib (10 nM) with N-acetylcysteine (1 mM, Sigma-Aldrich) or myricetin (200 µM, Selleck Chemicals). The effect of heat on bortezomib treated GBM cells was assessed by inducing 42 centigrade heat shock during 4 hours concomi-

tantly with bortezomib (10 nM) addition (Figure S4D). For each cell culture, cells were seeded in separate plates for control (37°C) and heat treatment (42°C). Primaria 96-well plates (VWR) were coated with laminin and incubated for 30 min at 37°C, before 5000 cells per well were seeded and incubated overnight at 37°C before treatment. For each cell culture, bortezomib (22 nM) and corresponding control DMSO were added to all plates, and the heating plates were incubated at 42°C for 4-, 24- and 48 hours, while their individual control plates were incubated at 37°C. Viability read was performed using the Wallac Victor 1420 multilabel counter (Perkin Elmer). To assess potential synergism between bortezomib and other compounds (Figure 7A-E), 10 GBM cultures were seeded in 96 well plates 5.000 cells/well and allowed to attach overnight. The next day, two proteasome inhibitors, bortezomib (1 μM) and marizomib (1 μM) were added in 6x6 pairwise combinations with 25 drugs identified in our integrative data analysis (drugs and dose ranges in Table S6). The highest concentration of each drug was set to around twofold the IC50 value identified in the literature. Cells in the control wells were treated with DMSO (0.1 %, corresponding to 10 μM drug; or highest concentration of the drug dilutions, but not exceeding 0.3 %). After 72h incubation alamarBlue® cell viability reagent (Thermo Fisher Scientific) was added and fluorescent readout made by Wallac 1420 Victor2 (Perkin Elmer). The resulting viability data was used to compute Combination Index scores as previously described (Schmidt et al., 2016). For further validation in a 3D tumor model over an extended time period, combinations of bortezomib with navitoclax or milciclib were selected for treatment of one bortezomib sensitive and one bortezomib resistant cell line over 10 days.

Sphere growth combination treatments

For Figure 7F-H, a total of 2000 cells from GBM cultures U3013MG and U3008MG were seeded in PrimeSurface 96U S-BIO plates (MoBiTech) in NSC medium with 2.5% matrigel basement membrane matrix (Corning). Following a short centrifugation step (30 sec at 1000 rpm), cells were incubated for two days to allow sphere formation before adding treatments consisting of vehicle control, single drugs or combinations of bortezomib with navitoclax or milciclib diluted in DMSO. An initial dose-response screen with the single drugs and combinations in three-fold dilutions spanning a dose range from 100-1 nM (bortezomib), 1-0.11 μM (navitoclax) and 2-0.22 μM (milciclib) with two replicates per well was performed to select the most efficient combinations for a second phase experiment with seven replicate per treatment condition. In the second phase, two concentrations of bortezomib (3 and 10 nM) were combined with three different concentrations of navitoclax (1 μM, 0.33 μM and 0.11 μM) or milciclib (2 μM, 0.66 μM, 0.22 μM). Images were acquired with the Phase and Brightfield channels every 6 hours for an additional 10 days on the IncuCyte S3 instrument (Sartorius) using the spheroid scan module with the 4x objective. Brightfield channel images were segmented using the IncuCyte 2019B Rev2 software and the largest sphere area in each image was measured. Sphere size in cells treated with drug combinations was compared to the single bortezomib treatments using a one-way ANOVA with Dunnett's multiple comparisons test. Single drug treatments were also compared to the combination treatment using

Student's t-tests. Statistical analyses were done in GraphPad Prism version 7.05.

BrdU cell cycle flow cytometric analysis of bortezomib treated GBM cultures

For Figure S5, immunofluorescent staining of incorporated bromodeoxyuridine (BrdU) was performed using BrdU-FITC specific antibodies according to the manufacturer's instructions (BD Pharmingen, 559619) coupled with 7-amino-actinomycin (7-AAD) staining to permit cell cycle position analysis of cells with actively synthesizing DNA. Two proteasome inhibitor sensitive and two proteasome inhibitor-resistant GBM cultures were treated with DMSO vehicle, 10 or 50 nM bortezomib for 24 hours. During the final 1 hour of cultures, the cells were pulsed with 10 μM of BrdU before processing according to the BrdU Flow Kit protocol. Cell-associated BrdU levels and DNA content was measured on a CytoFLEX platform (Beckman Coulter) equipped with a 488-nm laser and analyzed using the CytExpert software version 2.4.

QUANTIFICATION AND STATISTICAL ANALYSIS

Algorithms for glioblastoma subtype assignment

Four methods for subtype assignment were combined by a weighted majority vote to designate one subtype for each primary GBM culture. Using the Verhaak(Verhaak et al., 2010) gene signature, NTP(Hoshida, 2010), ssGSEA(Barbie et al., 2009), k-NN(Xie et al., 2015), and nearest centroid were run using 1000 bootstrap runs resampling cell cultures. A majority vote over the 1000 runs gave the subtype vote for each classifier.

Drug target annotation

We annotated our drug library by Chemical Abstract Service (CAS) identifier, International Chemical Identifier (InChI) and STITCH database (CIDs/CIDm) identifiers. As a secondary source, we linked our library to the Drug Repurposing Hub. Target assignments were derived from the Drug Repurposing hub and STITCH. In the latter case, target assignments are gradual, and we used all targets with a score of at least 700/1000.

Algorithms for drug activity similarity and cluster analysis

From the 1544 compounds in Phase 1, 212 were selected based on their activity. Using drug targets annotated as described above, a randomization test (randomizing the drug-target annotations 10000 times) was run to derive an empirical p-value for the frequency of targets selected among the 212 drugs. This resulted in 75 targets with an empirical p-value of less than 0.05. The most highly enriched targets are shown in Figure 2A. Clustering of cell cultures and drugs was performed by compiling a matrix of mean viability across doses for each drug

in each cell culture (cell cultures x compounds). To define subgroups of cell cultures, consensus clustering (Wilkerson and Hayes, 2010) using hierarchical clustering and Pearson distance metric was implemented using the ConsensusClusterPlus package in R Bioconductor. When clustering cell cultures, only the 80 compounds in the intersect between Phase 2 and Phase 3 was used. The optimal number of clusters was selected based on the diagnostic plots generated in the consensus clustering procedure (Figure S2A). To cluster drugs, a hierarchical clustering with Pearson distance metric and average linkage was used. The pairwise distances were computed omitting missing values. The final clusters were obtained using the *cutreeDynamicTree* function from the *dynamicTreeCut* package in R with the option *deepSplit* set to TRUE (Langfelder et al., 2008) and the minimum module size set to 5. For the heatmap in Figure 2, missing values were imputed using the *impute-knn* method in R, but the imputed values were not used in the clustering. A standard PCA solver (Matlab) was used for PCA calculations (Figure 4A,B, Figure In cases where more than one data type was used, all data were Z-transformed and stacked into a single matrix, before PCA.

Algorithms for construction of biomarker-drug network: drug response prediction based on multi-omic data

Prediction of drug response (quantified as the AUC score for each cell culture and drug) was performed using Random Forest (RF) (Breiman, 2001) and Elastic-Net (**?**) methods implemented in R (*randomForest*, *glmnet*). Predictions were run for each drug separately (predicting one drug at a time), and using each datatype (mRNA expression, CNA, methylation, mutation) individually and in all unique combinations (e.g. CNA-methylation, methylation-mutation, methylation-mutation-CNA). For methylation data, the set of probes was reduced by removing probes methylated above an average value of 0.4 in reference brain using data from GEO series GSE41826 (Guintivano et al., 2013). Methylation was then summarized at the gene level by averaging the values of methylation probes in CpG islands within 1500 bases of the gene TSS. Gene level mutation data were filtered to include only genes with at least two mutated cases. Leave-one-out (LOO) cross-validation was used to access the prediction performance by computing the Pearson correlation between the predicted and true values. Within each LOO-fold, internal cross-validation was used to select method parameters (e.g. lambda value for Elastic-Net). For each LOO-fold the variable importance was recorded (variable importance measure for RF and the absolute value of the Elastic-Net coefficient for Elastic-Net) and averaged over all LOO-folds for a particular drug. To construct the drug-variable network a variable was linked to a drug if the drug response was predicted with a Pearson correlation value above 0.2 and if that variable was among the top 50 most important variables for at least one prediction instance. The rather low threshold is used to encourage common predictors between drugs, and to allow for subsequent filtering of the network. To evaluate the impact of cross-validation method we compared 10-fold and leave-one-out CV using elastic net and expression data as the predictor. The 10-fold CV was averaged over 1000 runs. The prediction performance (CV-R) between the CV showed a Pearson correlation of 0.87. For each drug, a GSEA analysis (Subramanian et al., 2005) using

the javaGSEA Jar file v 3.0 and MSigDB Hallmark gene sets (Liberzon et al., 2015), was performed using the gene expression data (filtered to the 10000 genes with highest standard deviation across cell cultures) with the drug response as a continuous phenotype (1000 permutations of the phenotype with Pearson correlation metric). A drug is linked to an MSigDB pathway if the FDR q-value is less than 0.25. The links between drugs and MSigDB pathways were then added to the total network.

Algorithms for scoring drug synergism

The effect on viability of each drug dose was calculated as a viability ratio W = (Ytreated-Yblank)/(Ycontrol-Yblank), where Ytreated represents the fluorescence signal in treated wells, Ycontrol the signal in vehicle-treated (DMSO) wells, and Yblank is the technical background measured as the signal in cell-free (medium only) wells. Since drug pairs were analyzed across 6x6 pairwise combinations, we used a summary statistic defined as the minimum among the 6x6 epsilon values. Applied to the same data, we used the combination index, CI, defined as $CI(W) = d_a(W)/D_a(W) + d_b(W)/D_b(W)$, where $D_a(W)$ and $D_b(W)$ are the single-agent dose of drugs a and b needed to reduce viability to level W, and $d_a(W)$, $d_b(W)$ are the doses of a and b needed to reduce viability to level W, when used as a combination. For the single dose data in the sphere experiments (Figure 7G,H), the simpler Bliss method was used, whereby the combination phenotype W_{ab} is compared to its naive expectation, defined by the product $W_a W_b$.

KEY RESOURCES TABLE

Supplemental Excel File Legends

Table S1: overview of primary glioblastoma cell lines and data generated.

Table S2: annotated list of compounds with related properties. The Excel sheet contains compound information for the screening library. It comprises (i) Compound metadata (columns 1-9), including name, CAS and SMILES identifies; (ii) target and mechanism-of-action information (columns 10-19) as obtained from the STITCH and Drug Repurposing Hub databases and other sources; (iii) statistics from automated Pubmed searches (columns 20-24), indicating the number of publications involving each compound (as mentioned in the abstract or title) overall and co-mentioned with terms like 'glioblastoma'; and, (iv) statistics from the drug screen, including average AUC score, and CV-R as explained in each heading.

Table S3: summary statistics of predictive power for different drug classes. Drug categories whose response can be predicted in primary GBM cells. n is the number of drugs in each category. CV-R is the average cross-validation correlation per drug category. P values: Student's t-test.

Table S4: p53 status of each cell line as determined by Sanger sequencing.

Table S5: qPCR primers used for figure S4A.

Table S6: doses used for each drug in the potentiation experiments in Figure 7.

References

1000 Genomes Project Consortium, Auton, A., Brooks, L. D., Durbin, R. M., Garrison, E. P., Kang, H. M., Korbel, J. O., Marchini, J. L., McCarthy, S., McVean, G. A. and Abecasis, G. R. (2015). A global reference for human genetic variation. Nature *526*, 68–74.

Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J., Destree, A., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S. and Elliott, P. J. (1999). Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. *59*, 2615–2622.

Ahmad, F., Dixit, D., Sharma, V., Kumar, A., Joshi, S. D., Sarkar, C. and Sen, E. (2016). Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma. Cell Death Dis *7*, e2213.

Allen, M., Bjerke, M., Edlund, H., Nelander, S. and Westermark, B. (2016). Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med *8*, 354re3.

Almstedt, E., Elgendy, R., Hekmati, N., Rosen, E., Warn, C., Olsen, T. K., Dyberg, C., Doroszko, M., Larsson, I., Sundstrom, A., Arsenian Henriksson, M., Pahlman, S., Bexell, D., Vanlandewijck, M., Kogner, P., Jornsten, R., Krona, C. and Nelander, S. (2020). Integrative discovery of treatments for high-risk neuroblastoma. Nat Commun *11*, 71.

Asklund, T., Kvarnbrink, S., Holmlund, C., Wibom, C., Bergenheim, T., Henriksson, R. and Hedman, H. (2012). Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. Anticancer Res. *32*, 2407–2413.

Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., Frohling, S., Chan, E. M., Sos, M. L., Michel, K., Mermel, C., Silver, S. J., Weir, B. A., Reiling, J. H., Sheng, Q., Gupta, P. B., Wadlow, R. C., Le, H., Hoersch, S., Wittner, B. S., Ramaswamy, S., Livingston, D. M., Sabatini, D. M., Meyerson, M., Thomas, R. K., Lander, E. S., Mesirov, J. P., Root, D. E., Gilliland, D. G., Jacks, T. and Hahn, W. C. (2009). Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature *462*, 108–112.

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehar, J., Kryukov, G. V., Sonkin, D., Reddy, A., Liu, M., Murray, L., Berger, M. F., Monahan, J. E., Morais, P., Meltzer, J., Korejwa, A., Jane-Valbuena, J., Mapa, F. A., Thibault, J., Bric-Furlong, E., Raman, P., Shipway, A., Engels, I. H., Cheng, J., Yu, G. K., Yu, J., Aspesi, P., de Silva, M., Jagtap, K., Jones, M. D., Wang, L., Hatton, C., Palescandolo, E., Gupta, S., Mahan, S., Sougnez, C., Onofrio, R. C., Liefeld, T., MacConaill, L., Winckler, W., Reich, M., Li, N., Mesirov, J. P., Gabriel, S. B., Getz, G., Ardlie, K., Chan, V., Myer, V. E., Weber, B. L., Porter, J., Warmuth, M., Finan, P., Harris, J. L., Meyerson, M., Golub, T. R., Morrissey, M. P., Sellers, W. R., Schlegel, R. and Garraway, L. A. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature *483*, 603–607.

Basu, A., Bodycombe, N. E., Cheah, J. H., Price, E. V., Liu, K., Schaefer, G. I., Ebright, R. Y., Stewart, M. L., Ito, D., Wang, S., Bracha, A. L., Liefeld, T., Wawer, M., Gilbert, J. C., Wilson, A. J., Stransky, N., Kryukov, G. V., Dancik, V., Barretina, J., Garraway, L. A., Hon, C. S., Munoz, B., Bittker, J. A., Stockwell, B. R., Khabele, D., Stern, A. M., Clemons, P. A., Shamji, A. F. and Schreiber, S. L. (2013). An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell *154*, 1151–1161.

Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N., Nakano, K., Bartrons, R., Gottlieb, E. and Vousden, K. H. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell *126*, 107–120.

Breiman, L. (2001). Random forests. Machine learning *45*, 5–32.

Brennan, C. W., Verhaak, R. G., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., Beroukhim, R., Bernard, B., Wu, C. J., Genovese, G., Shmulevich, I., Barnholtz-Sloan, J., Zou, L., Vegesna, R., Shukla, S. A., Ciriello, G., Yung, W. K., Zhang, W., Sougnez, C., Mikkelsen, T., Aldape, K., Bigner, D. D., Van Meir, E. G., Prados, M., Sloan, A., Black, K. L., Eschbacher, J., Finocchiaro, G., Friedman, W., Andrews, D. W., Guha, A., Iacocca, M., O'Neill, B. P., Foltz, G., Myers, J., Weisenberger, D. J., Penny, R., Kucherlapati, R., Perou, C. M., Hayes, D. N., Gibbs, R., Marra, M., Mills, G. B., Lander, E., Spellman, P., Wilson, R., Sander, C., Weinstein, J., Meyerson, M., Gabriel, S., Laird, P. W., Haussler, D., Getz, G., Chin, L., Benz, C., Barnholtz-Sloan, J., Barrett, W., Ostrom, Q., Wolinsky, Y., Black, K. L., Bose, B., Boulos, P. T., Boulos, M., Brown, J., Czerinski, C., Eppley, M., Iacocca, M., Kempista, T., Kitko, T., Koyfman, Y., Rabeno, B., Rastogi, P., Sugarman, M., Swanson, P., Yalamanchii, K., Otey, I. P., Liu, Y. S., Xiao, Y., Auman, J. T., Chen, P. C., Hadjipanayis, A., Lee, E., Lee, S., Park, P. J., Seidman, J., Yang, L., Kucherlapati, R., Kalkanis, S., Mikkelsen, T., Poisson, L. M., Raghunathan, A., Scarpace, L., Bernard, B., Bressler, R., Eakin, A., Iype, L., Kreisberg, R. B., Leinonen, K., Reynolds, S., Rovira, H., Thorsson, V., Shmulevich, I., Annala, M. J., Penny, R., Paulauskis, J., Curley, E., Hatfield, M., Mallery, D., Morris, S., Shelton, T., Shelton, C., Sherman, M., Yena, P., Cuppini, L., DiMeco, F., Eoli, M., Finocchiaro, G., Maderna, E., Pollo, B., Saini, M., Balu, S., Hoadley, K. A., Li, L., Miller, C. R., Shi, Y., Topal, M. D., Wu, J., Dunn, G., Giannini, C., O'Neill, B. P., Aksoy, B. A., Antipin, Y., Borsu, L., Berman, S. H., Brennan, C. W., Cerami, E., Chakravarty, D., Ciriello, G., Gao, J., Gross, B., Jacobsen, A., Ladanyi, M., Lash, A., Liang, Y., Reva, B., Sander, C., Schultz, N., Shen, R., Socci, N. D., Viale, A., Ferguson, M. L., Chen, Q. R., Demchok, J. A., Dillon, L. A., Shaw, K. R., Sheth, M., Tarnuzzer, R., Wang, Z., Yang, L., Davidsen, T., Guyer, M. S., Ozenberger, B. A., Sofia, H. J., Bergsten, J., Eckman, J., Harr, J., Myers, J., Smith, C., Tucker, K., Winemiller, C., Zach, L. A., Ljubimova, J. Y., Eley, G., Ayala, B., Jensen, M. A., Kahn, A., Pihl, T. D., Pot, D. A., Wan, Y., Eschbacher, J., Foltz, G., Hansen, N., Hothi, P., Lin, B., Shah, N., Yoon, J. G., Lau, C., Berens, M., Ardlie, K., Beroukhim, R., Carter, S. L., Cherniack, A. D., Noble, M., Cho, J., Cibulskis, K., DiCara, D., Frazer, S., Gabriel, S. B., Gehlenborg, N., Gentry, J., Heiman, D., Kim, J., Jing, R., Lander, E. S., Lawrence, M., Lin, P., Mallard, W., Meyerson, M., Onofrio, R. C., Saksena, G., Schumacher, S., Sougnez, C., Stojanov, P., Tabak, B., Voet, D., Zhang, H., Zou, L., Getz, G., Dees,

N. N., Ding, L., Fulton, L. L., Fulton, R. S., Kanchi, K. L., Mardis, E. R., Wilson, R. K., Baylin, S. B., Andrews, D. W., Harshyne, L., Cohen, M. L., Devine, K., Sloan, A. E., VandenBerg, S. R., Berger, M. S., Prados, M., Carlin, D., Craft, B., Ellrott, K., Goldman, M., Goldstein, T., Grifford, M., Haussler, D., Ma, S., Ng, S., Salama, S. R., Sanborn, J. Z., Stuart, J., Swatloski, T., Waltman, P., Zhu, J., Foss, R., Frentzen, B., Friedman, W., McTiernan, R., Yachnis, A., Hayes, D. N., Perou, C. M., Zheng, S., Vegesna, R., Mao, Y., Akbani, R., Aldape, K., Bogler, O., Fuller, G. N., Liu, W., Liu, Y., Lu, Y., Mills, G., Protopopov, A., Ren, X., Sun, Y., Wu, C. J., Yung, W. K., Zhang, W., Zhang, J., Chen, K., Weinstein, J. N., Chin, L., Verhaak, R. G., Noushmehr, H., Weisenberger, D. J., Bootwalla, M. S., Lai, P. H., Triche, T. J., Van Den Berg, D. J., Laird, P. W., Gutmann, D. H., Lehman, N. L., VanMeir, E. G., Brat, D., Olson, J. J., Mastrogianakis, G. M., Devi, N. S., Zhang, Z., Bigner, D., Lipp, E. and McLendon, R. (2013). The somatic genomic landscape of glioblastoma. Cell *155*, 462–477.

Brown, P. D., Krishnan, S., Sarkaria, J. N., Wu, W., Jaeckle, K. A., Uhm, J. H., Geoffroy, F. J., Arusell, R., Kitange, G., Jenkins, R. B., Kugler, J. W., Morton, R. F., Rowland, K. M., Mischel, P., Yong, W. H., Scheithauer, B. W., Schiff, D., Giannini, C., Buckner, J. C., Soori, G. S., Dakhil, S. R., Fitch, T. R., Windschitl, H. E., Flynn, P. J., Anderson, D. M., Nair, S., Nikcevich, D. A., Wender, D. B., Stella, P. J. and Jillella, A. P. (2008). Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol. *26*, 5603–5609.

Budanov, A. V. (2011). Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling. Antioxid. Redox Signal. *15*, 1679–1690.

Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S. and Getz, G. (2013). Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. *31*, 213–219.

Corsello, S. M., Bittker, J. A., Liu, Z., Gould, J., McCarren, P., Hirschman, J. E., Johnston, S. E., Vrcic, A., Wong, B., Khan, M., Asiedu, J., Narayan, R., Mader, C. C., Subramanian, A. and Golub, T. R. (2017). The Drug Repurposing Hub: a next-generation drug library and information resource. Nat. Med. *23*, 405–408.

Dabiri, Y., Kalman, S., G?rth, C. M., Kim, J. Y., Mayer, V. and Cheng, X. (2017). The essential role of TAp73 in bortezomib-induced apoptosis in p53-deficient colorectal cancer cells. Sci Rep *7*, 5423.

DeBord, L. C., Pathak, R. R., Villaneuva, M., Liu, H. C., Harrington, D. A., Yu, W., Lewis, M. T. and Sikora, A. G. (2018). The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research. Am J Cancer Res *8*, 1642–1660.

Di, K., Lloyd, G. K., Abraham, V., MacLaren, A., Burrows, F. J., Desjardins, A., Trikha, M. and Bota, D. A.

(2016). Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Neuro-oncology *18*, 840–848.

Eisenberg, E. and Levanon, E. Y. (2003). Human housekeeping genes are compact. Trends Genet. *19*, 362–365.

Forte, I. M., Indovina, P., Iannuzzi, C. A., Cirillo, D., Di Marzo, D., Barone, D., Capone, F., Pentimalli, F. and Giordano, A. (2019). Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Int. J. Oncol. *54*, 2189–2199.

Gagnon-Bartsch, J. A. and Speed, T. P. (2012). Using control genes to correct for unwanted variation in microarray data. Biostatistics *13*, 539–552.

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., Liu, Q., Iorio, F., Surdez, D., Chen, L., Milano, R. J., Bignell, G. R., Tam, A. T., Davies, H., Stevenson, J. A., Barthorpe, S., Lutz, S. R., Kogera, F., Lawrence, K., McLaren-Douglas, A., Mitropoulos, X., Mironenko, T., Thi, H., Richardson, L., Zhou, W., Jewitt, F., Zhang, T., O'Brien, P., Boisvert, J. L., Price, S., Hur, W., Yang, W., Deng, X., Butler, A., Choi, H. G., Chang, J. W., Baselga, J., Stamenkovic, I., Engelman, J. A., Sharma, S. V., Delattre, O., Saez-Rodriguez, J., Gray, N. S., Settleman, J., Futreal, P. A., Haber, D. A., Stratton, M. R., Ramaswamy, S., McDermott, U. and Benes, C. H. (2012). Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature *483*, 570–575.

Guintivano, J., Aryee, M. J. and Kaminsky, Z. A. (2013). A cell epigenotype specific model for the correction of brain cellular heterogeneity bias and its application to age, brain region and major depression. Epigenetics *8*, 290–302.

Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J. and Anderson, K. C. (2001). The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. *61*, 3071–3076.

Hoshida, Y. (2010). Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS ONE *5*, e15543.

Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Goncalves, E., Barthorpe, S., Lightfoot, H., Cokelaer, T., Greninger, P., van Dyk, E., Chang, H., de Silva, H., Heyn, H., Deng, X., Egan, R. K., Liu, Q., Mironenko, T., Mitropoulos, X., Richardson, L., Wang, J., Zhang, T., Moran, S., Sayols, S., Soleimani, M., Tamborero, D., Lopez-Bigas, N., Ross-Macdonald, P., Esteller, M., Gray, N. S., Haber, D. A., Stratton, M. R., Benes, C. H., Wessels, L. F. A., Saez-Rodriguez, J., McDermott, U. and Garnett, M. J. (2016). A Landscape of Pharmacogenomic Interactions in Cancer. Cell *166*, 740–754.

Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L. and Wilson, R. K. (2012). VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. *22*, 568–576.

Kutalik, Z., Beckmann, J. S. and Bergmann, S. (2008). A modular approach for integrative analysis of large-scale gene-expression and drug-response data. Nat. Biotechnol. *26*, 531–539.

Langfelder, P., Zhang, B. and Horvath, S. (2008). Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R. Bioinformatics *24*, 719–720.

Larson, D. E., Harris, C. C., Chen, K., Koboldt, D. C., Abbott, T. E., Dooling, D. J., Ley, T. J., Mardis, E. R., Wilson, R. K. and Ding, L. (2012). SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics *28*, 311–317.

Lee, E. Q., Kaley, T. J., Duda, D. G., Schiff, D., Lassman, A. B., Wong, E. T., Mikkelsen, T., Purow, B. W., Muzikansky, A., Ancukiewicz, M., Huse, J. T., Ramkissoon, S., Drappatz, J., Norden, A. D., Beroukhim, R., Weiss, S. E., Alexander, B. M., McCluskey, C. S., Gerard, M., Smith, K. H., Jain, R. K., Batchelor, T. T., Ligon, K. L. and Wen, P. Y. (2015). A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin. Cancer Res. *21*, 3610–3618.

Lee, J. K., Liu, Z., Sa, J. K., Shin, S., Wang, J., Bordyuh, M., Cho, H. J., Elliott, O., Chu, T., Choi, S. W., Rosenbloom, D. I. S., Lee, I. H., Shin, Y. J., Kang, H. J., Kim, D., Kim, S. Y., Sim, M. H., Kim, J., Lee, T., Seo, Y. J., Shin, H., Lee, M., Kim, S. H., Kwon, Y. J., Oh, J. W., Song, M., Kim, M., Kong, D. S., Choi, J. W., Seol, H. J., Lee, J. I., Kim, S. T., Park, J. O., Kim, K. M., Song, S. Y., Lee, J. W., Kim, H. C., Lee, J. E., Choi, M. G., Seo, S. W., Shim, Y. M., Zo, J. I., Jeong, B. C., Yoon, Y., Ryu, G. H., Kim, N. K. D., Bae, J. S., Park, W. Y., Lee, J., Verhaak, R. G. W., Iavarone, A., Lee, J., Rabadan, R. and Nam, D. H. (2018). Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat. Genet. *50*, 1399–1411.

Liberzon, A., Birger, C., Thorvaldsdottir, H., Ghandi, M., Mesirov, J. P. and Tamayo, P. (2015). The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst *1*, 417–425.

Ling, Y. H., Liebes, L., Zou, Y. and Perez-Soler, R. (2003). Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J. Biol. Chem. *278*, 33714–33723.

Lipchick, B. C., Fink, E. E. and Nikiforov, M. A. (2016). Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol. Res. *105*, 210–215.

Mayrhofer, M., DiLorenzo, S. and Isaksson, A. (2013). Patchwork: allele-specific copy number analysis of whole-genome sequenced tumor tissue. Genome Biol. *14*, R24.

Miyahara, K., Kazama, H., Kokuba, H., Komatsu, S., Hirota, A., Takemura, J., Hirasawa, K., Moriya, S., Abe, A., Hiramoto, M., Ishikawa, T. and Miyazawa, K. (2016). Targeting bortezomib-induced aggresome

formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines. Int. J. Oncol. *49*, 1848–1858.

Moriya, S., Komatsu, S., Yamasaki, K., Kawai, Y., Kokuba, H., Hirota, A., Che, X. F., Inazu, M., Gotoh, A., Hiramoto, M. and Miyazawa, K. (2015). Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress mediated cell death in multiple myeloma cells. Int. J. Oncol. *46*, 474–486.

Nikolaev, S., Santoni, F., Garieri, M., Makrythanasis, P., Falconnet, E., Guipponi, M., Vannier, A., Radovanovic, I., Bena, F., Forestier, F., Schaller, K., Dutoit, V., Clement-Schatlo, V., Dietrich, P. Y. and Antonarakis, S. E. (2014). Extrachromosomal driver mutations in glioblastoma and low-grade glioma. Nat Commun *5*, 5690.

Page, B., Page, M. and Noel, C. (1993). A new fluorometric assay for cytotoxicity measurements in-vitro. Int. J. Oncol. *3*, 473–476.

Pfaff, E., Remke, M., Sturm, D., Benner, A., Witt, H., Milde, T., von Bueren, A. O., Wittmann, A., Schottler, A., Jorch, N., Graf, N., Kulozik, A. E., Witt, O., Scheurlen, W., von Deimling, A., Rutkowski, S., Taylor, M. D., Tabori, U., Lichter, P., Korshunov, A. and Pfister, S. M. (2010). TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J. Clin. Oncol. *28*, 5188–5196.

Pollard, S. M., Yoshikawa, K., Clarke, I. D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head, R., Lee, M., Bernstein, M., Squire, J. A., Smith, A. and Dirks, P. (2009). Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell *4*, 568–580.

Qiang, W., Sui, F., Ma, J., Li, X., Ren, X., Shao, Y., Liu, J., Guan, H., Shi, B. and Hou, P. (2017). Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a. Endocrine *56*, 98–108.

Reardon, D. A., Nabors, L. B., Mason, W. P., Perry, J. R., Shapiro, W., Kavan, P., Mathieu, D., Phuphanich, S., Cseh, A., Fu, Y., Cong, J., Wind, S., Eisenstat, D. D., Reardon, D., Wen, P., Mikkelson, T., Portnow, J., Giglio, P., Lai, R., New, P., Shapiro, W., Phuphanich, S., Nabors, L., Fink, K., Chowdhary, S., Madison, M., Taylor, L., Hadjipanayis, C., Madarnas, Y., Kavan, P., Perry, J., Mason, W., Easaw, J., Vallieres, I., Mathieu, D., Hirte, H., Whitlock, P., Eisenstat, D., MacNeil, M. V., Bolonna, A., Reardon, D. A., Cseh, A., Fu, Y., Cong, J., Wind, S., Eisenstat, D. D., Nabors, L. B., Mason, W. P., Perry, J. R., Shapiro, W., Kavan, P., Mathieu, D. and Phuphanich, S. (2015). Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-oncology *17*, 430–439.

Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J. L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J. F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W. S., Boral, A. L., Esseltine, D. L., Porter, J. B., Schenkein, D. and Anderson, K. C. (2005). Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. *352*, 2487–2498.

Schmidt, L., Baskaran, S., Johansson, P., Padhan, N., Matuszewski, D., Green, L. C., Elfineh, L., Wee, S., Haggblad, M., Martens, U., Westermark, B., Forsberg-Nilsson, K., Uhrbom, L., Claesson-Welsh, L., Andang, M., Sintorn, I. M., Lundgren, B., Lonnstedt, I., Krona, C. and Nelander, S. (2016). Case-specific potentiation of glioblastoma drugs by pterostilbene. Oncotarget *7*, 73200–73215.

Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., Alexander, B., Li, A., Montgomery, P., Wawer, M. J., Kuru, N., Kotz, J. D., Hon, C. S., Munoz, B., Liefeld, T., Dan?ik, V., Bittker, J. A., Palmer, M., Bradner, J. E., Shamji, A. F., Clemons, P. A. and Schreiber, S. L. (2015). Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discov *5*, 1210–1223.

Seol, D. W. (2011). p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem. Biophys. Res. Commun. *416*, 222–225.

Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B. and Ideker, T. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. *13*, 2498–2504.

Spiegelberg, D., Mortensen, A. C., Lundsten, S., Brown, C. J., Lane, D. P. and Nestor, M. (2018). The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors. Cancer Res. *78*, 5084–5093.

Strauss, S. J., Higginbottom, K., J?liger, S., Maharaj, L., Allen, P., Schenkein, D., Lister, T. A. and Joel, S. P. (2007). The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res. *67*, 2783–2790.

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E. and Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. *352*, 987–996.

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S. and Mesirov, J. P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. *102*, 15545–15550.

Tao, W. and Levine, A. J. (1999). P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. U.S.A. *96*, 6937–6941.

Taylor, O. G., Brzozowski, J. S. and Skelding, K. A. (2019). Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets. Front Oncol *9*, 963.

Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H. S., Hodgson, J. G., James, C. D., Sarkaria, J. N., Brennan, C., Kahn, A., Spellman, P. T., Wilson, R. K., Speed, T. P., Gray, J. W., Meyerson, M., Getz, G., Perou, C. M. and Hayes, D. N. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell *17*, 98–110.

Wang, K., Li, M. and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. *38*, e164.

Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L., deCarvalho, A. C., Lyu, S., Li, P., Li, Y., Barthel, F., Cho, H. J., Lin, Y. H., Satani, N., Martinez-Ledesma, E., Zheng, S., Chang, E., Sauve, C. G., Olar, A., Lan, Z. D., Finocchiaro, G., Phillips, J. J., Berger, M. S., Gabrusiewicz, K. R., Wang, G., Eskilsson, E., Hu, J., Mikkelsen, T., DePinho, R. A., Muller, F., Heimberger, A. B., Sulman, E. P., Nam, D. H. and Verhaak, R. G. W. (2017). Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell *32*, 42–56.

Wilkerson, M. D. and Hayes, D. N. (2010). ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics *26*, 1572–1573.

Xie, Y., Bergstrom, T., Jiang, Y., Johansson, P., Marinescu, V. D., Lindberg, N., Segerman, A., Wicher, G., Niklasson, M., Baskaran, S., Sreedharan, S., Everlien, I., Kastemar, M., Hermansson, A., Elfineh, L., Libard, S., Holland, E. C., Hesselager, G., Alafuzoff, I., Westermark, B., Nelander, S., Forsberg-Nilsson, K. and Uhrbom, L. (2015). The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes. EBioMedicine *2*, 1351–1363.

Xue, Y., Barker, N., Hoon, S., He, P., Thakur, T., Abdeen, S. R., Maruthappan, P., Ghadessy, F. J. and Lane, D. P. (2019). Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of both Normal and Tumor Tissues In Vivo. Cancer Res.